Microba Life Sciences Ltd. analyzes the microbiome to discover novel therapeutics and develop new diagnostic tools. Its therapeutic discovery platform,analysis platform and discovery platform uses human data and informatic approaches to connect microbial genotype to human phenotype. The firm offers microbiome testing services via distribution partners, and is working on microbial cell therapies for inflammatory bowel disease, cancer immunotherapy and autoimmune disease. The company was founded by Gene Tyson and Philip Hugenholtz in 2017 and is headquartered in Brisbane, Australia.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company